Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Typhoid-Paratyphoid Vaccines: Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.Vaccines, Attenuated: Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Combined: Two or more vaccines in a single dosage form.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Papillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.Meningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.Hepatitis B Vaccines: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.Measles Vaccine: A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)Haemophilus Vaccines: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Rabies Vaccines: Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.Rotavirus Vaccines: Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.Cholera Vaccines: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.Smallpox Vaccine: A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)Tuberculosis Vaccines: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Chickenpox Vaccine: A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.Diphtheria-Tetanus-Pertussis Vaccine: A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.Mumps Vaccine: Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.Hepatitis A Vaccines: Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).Immunization Schedule: Schedule giving optimum times usually for primary and/or secondary immunization.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Measles-Mumps-Rubella Vaccine: A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.Streptococcal Vaccines: Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.Anthrax Vaccines: Vaccines or candidate vaccines used to prevent ANTHRAX.Dengue Vaccines: Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.Vaccines, Virosome: Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).

The effect of route of immunization on the lapine immune response to killed Pasteurella haemolytica and the influence of aerosol challenge with the live organism. (1/3096)

Appearance of anti-Pasteurella haemolytica antibody in the serum and broncho-alveolar washings of rabbits is independent of the route of immunization and is similar in both locations. The most influential factor in development of a humoral response is exposure to live P. haemolytica and prior exposure to the killed bacterium has no significant effect upon titre determined following aerosol challenge with live organisms.  (+info)

Immune response capacity after human splenic autotransplantation: restoration of response to individual pneumococcal vaccine subtypes. (2/3096)

OBJECTIVE: To evaluate features of general immune function, in particular the restoration of the humoral immune response to pneumococcal capsular polysaccharides, in humans undergoing a spleen autotransplantation after splenectomy because of trauma. SUMMARY BACKGROUND DATA: After splenectomy, patients have an increased risk of overwhelming infection or sepsis involving encapsulated bacteria such as pneumococci. The value of human spleen autotransplantation after splenectomy because of trauma has long been questioned. Mononuclear phagocyte system function appeared to be similar to that in splenectomized persons. The presence of specific antipneumococcal antibodies would allow other parts of the mononuclear phagocyte system, such as those in the liver, to phagocytose opsonized bacteria. METHODS: Ten consecutive patients undergoing splenectomy followed by autotransplantation were compared with the next 14 consecutive patients undergoing splenectomy alone. After a minimum of 6 months, the patients were vaccinated with 23-valent pneumococcal vaccine. Blood samples were taken at the time of vaccination and after 3 and 6 weeks for antipneumococcal capsular polysaccharides IgM and IgG enzyme-linked immunosorbent assay against types 3, 4, 6, 9, 14, and 23. Splenic regrowth was evaluated by scintigraphy. RESULTS: Surprisingly, several of the nonautotransplanted patients showed scintigraphic activity, indicating the presence of either accessory spleens or traumatic seeding (splenosis). Significant antibody titer increases (more than twofold) were found for both IgM and IgG in the autotransplanted patients. Splenectomized-only patients showed no significant increase in Ig levels in patients without splenic regrowth and partial improvement in patients with splenosis/accessory spleens. CONCLUSIONS: Considering this significant antipneumococcal antibody increase, spleen autotransplants can be expected to permit an adequate humoral response to pneumococcal infections and presumably also to other TI-2 antigens, and to protect against overwhelming postsplenectomy infection or sepsis.  (+info)

Paediatric, invasive pneumococcal disease in Switzerland, 1985-1994. Swiss Pneumococcal Study Group. (3/3096)

BACKGROUND: Cost effective use of new vaccines against pneumococcal disease in children requires detailed information about the local epidemiology of pneumococcal infections. METHODS: Data on 393 culture-confirmed cases of invasive pneumococcal infection in children (<17 years) hospitalized in Swiss paediatric clinics were collected retrospectively for the years 1985-1994. RESULTS: Meningitis (42%) was most frequent, followed by pneumonia (28%) and bacteraemia (26%). The overall annual incidence was 2.7 cases per 100000 children <17 years old and 11 cases per 100000 children <2 years old. Annual incidence rates were stable over the study period. Lethality was high for meningitis (8.6%) and bacteraemia (8.9%). A history of basal skull fracture was reported in 3.3% of children with pneumococcal meningitis. Residence in a rural region was associated with an increased risk of pneumococcal infection (relative risk = 1.45, 95% confidence interval: 1.01-2.00). CONCLUSIONS: Paediatric, invasive pneumococcal disease seems to be less frequent in Switzerland than in other European and non-European countries. This may be due to differences in diagnostic strategies and lower frequency of risk factors such as the use of day care. Children with a history of basal skull fracture are at increased risk for pneumococcal meningitis. Further investigation of the association of invasive pneumococcal infection with rural residence and the use of antibiotics for upper respiratory tract infections might give new insight into the dynamics of Streptococcus pneumoniae infection and the development of antibiotic resistance.  (+info)

Purification and cloning of a streptokinase from Streptococcus uberis. (4/3096)

A bovine plasminogen activator was purified from the culture supernatant of the bovine pathogen Streptococcus uberis NCTC 3858. After the final reverse-phase high-performance liquid chromatography step a single protein with a molecular mass of 32 kDa was detected in the active fraction. A partial peptide map was established, and degenerate primers were designed and used for amplification of fragments of the gene encoding the activator. Inverse PCR was subsequently used for obtaining the full-length gene. The S. uberis plasminogen activator gene (skc) encodes a protein consisting of 286 amino acids including a signal peptide of 25 amino acids. In an amino acid sequence comparison the cloned activator showed an identity of approximately 26% to the streptokinases isolated from Streptococcus equisimilis and Streptococcus pyogenes. Interestingly, the activator from S. uberis was found to lack the C-terminal domain possessed by the streptokinase from S. equisimilis. This is apparently a general feature of the streptokinases of this species; biochemical and genetic analysis of 10 additional strains of S. uberis revealed that 9 of these were highly similar to strain NCTC 3858. Sequencing of the skc gene from three of these strains indicated that the amino acid sequence of the protein is highly conserved within the species.  (+info)

Pathogenicity island 2 mutants of Salmonella typhimurium are efficient carriers for heterologous antigens and enable modulation of immune responses. (5/3096)

The potential use as vaccine delivery system of Salmonella typhimurium strains harboring defined mutations in the sseC (HH104) and sseD (MvP101) genes, which encode putative effector proteins of the type III secretion system of Salmonella pathogenicity island 2, was evaluated and compared with that of the well-characterized aroA mutant strain SL7207 by using beta-galactosidase (beta-Gal) as a model antigen. When orally administered to immune-competent or gamma interferon-deficient (IFN-gamma-/-) BALB/c mice, both mutants were found to be highly attenuated (50% lethal dose, >10(9) bacteria). Both strains were also able to efficiently colonize and persist in Peyer's patches. Immunization with HH104 and MvP101 triggered beta-Gal-specific serum and mucosal antibody responses equivalent to or stronger than those observed in SL7207-immunized mice. Although immunoglobulin G2 (IgG2) serum antibodies were dominant in all groups, IgG1 was also significantly increased in mice vaccinated with MvP101 and SL7207. Comparable beta-Gal-specific IgA and IgG antibodies were detected in intestinal lavages from mice immunized with the different strains. Antigen-specific CD4(+) T-helper cells were generated after vaccination with all vaccine prototypes; however, responses were significantly more efficient when HH104 and MvP101 were used (P < 0.05). Significantly higher levels of IFN-gamma were produced by restimulated spleen cells from mice immunized with HH104 than from those vaccinated with the MvP101 or SL7207 derivatives (P +info)

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. (6/3096)

Transcutaneous immunization (TCI) is a new technique that uses the application of vaccine antigens in a solution on the skin to induce potent antibody responses without systemic or local toxicity. We have previously shown that cholera toxin (CT), a potent adjuvant for oral and nasal immunization, can induce both serum and mucosal immunoglobulin G (IgG) and IgA and protect against toxin-mediated mucosal disease when administered by the transcutaneous route. Additionally, CT acts as an adjuvant for coadministered antigens such as tetanus and diphtheria toxoids when applied to the skin. CT, a member of the bacterial ADP-ribosylating exotoxin (bARE) family, is most potent as an adjuvant when the A-B subunits are present and functional. We now show that TCI induces secondary antibody responses to coadministered antigens as well as to CT in response to boosting immunizations. IgG antibodies to coadministered antigens were also found in the stools and lung washes of immunized mice, suggesting that TCI may target mucosal pathogens. Mice immunized by the transcutaneous route with tetanus fragment C and CT developed anti-tetanus toxoid antibodies and were protected against systemic tetanus toxin challenge. We also show that bAREs, similarly organized as A-B subunits, as well as the B subunit of CT alone, induced antibody responses to themselves when given via TCI. Thus, TCI appears to induce potent, protective immune responses to both systemic and mucosal challenge and offers significant potential practical advantages for vaccine delivery.  (+info)

Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. (7/3096)

Antibodies against the class 4 outer membrane protein (OMP) from Neisseria meningitidis have been purified from sera from vaccinees immunized with the Norwegian meningococcal group B outer membrane vesicle vaccine. The human sera and purified antibodies reacted strongly with the class 4 OMP in immunoblots, whereas experiments with whole bacteria showed only weak reactions, indicating that the antibodies mainly reacted with parts of the class 4 molecule that were not exposed. The purified human anti-class 4 OMP antibodies and the monoclonal antibodies (MAbs) were neither bactericidal nor opsonic against live meningococci. Three new MAbs against the class 4 OMP were generated and compared with other, previously described MAbs. Three linear epitopes in different regions of the class 4 OMP were identified by the reaction of MAbs with synthetic peptides. The MAbs showed no blocking effect on bactericidal activity of MAbs against other OMPs. However, one of the eight purified human anti-class 4 OMP antibody preparations, selected from immunoblot reactions among sera from 27 vaccinees, inhibited at high concentrations the bactericidal effect of a MAb against the class 1 OMP. However, these antibodies were not vaccine induced, as they were present also before vaccination. Therefore, this study gave no evidence that vaccination with a meningococcal outer membrane vesicle vaccine containing the class 4 OMP induces blocking antibodies. Our data indicated that the structure of class 4 OMP does not correspond to standard beta-barrel structures of integral OMPs and that no substantial portion of the OmpA-like C-terminal region of this protein is located at the surface of the outer membrane.  (+info)

Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. (8/3096)

A hybrid protein [Met-Ala-(His)6OprF190-342-OprI21-83] consisting of the mature outer membrane protein I (OprI) and amino acids 190 to 342 of OprF of Pseudomonas aeruginosa was expressed in Escherichia coli and purified by Ni2+ chelate-affinity chromatography. After safety and pyrogenicity evaluations in animals, four groups of eight adult human volunteers were vaccinated intramuscularly three times at 4-week intervals and revaccinated 6 months later with either 500, 100, 50, or 20 microg of OprF-OprI adsorbed onto A1(OH)3. All vaccinations were well tolerated. After the first vaccination, a significant rise of antibody titers against P. aeruginosa OprF and OprI was measured in volunteers receiving the 100- or the 500-microg dose. After the second vaccination, significant antibody titers were measured for all groups. Elevated antibody titers against OprF and OprI could still be measured 6 months after the third vaccination. The capacity of the elicited antibodies to promote complement binding and opsonization could be demonstrated by a C1q-binding assay and by the in vitro opsonophagocytic uptake of P. aeruginosa bacteria. These data support the continued development of an OprF-OprI vaccine for use in humans.  (+info)

*Artificial induction of immunity

Some diseases, such as tetanus, cause disease not by bacterial growth but by bacterial production of a toxin. Tetanus toxin is ... Vaccines - a Biography edited by Andrew W. Artenstein ISBN 978-1-4419-1107-0[page needed] ... Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine (Report). Centers for Disease ... Main articles: Smallpox vaccine and Edward Jenner. In 1796, Edward Jenner, a doctor and scientist who had practiced variolation ...

*Immunologic adjuvant

Vaxjo: Comprehensive vaccine adjuvant database.. References[edit]. *^ "Guideline on Adjuvants in Vaccines for Human Use" (PDF) ... components of bacterial cell walls, and endocytosed nucleic acids such as double-stranded RNA (dsRNA), single-stranded DNA ( ... Baylor NW, Egan W, Richman P (May 2002). "Aluminum salts in vaccines--US perspective". Vaccine. 20 Suppl 3 (Suppl 3): S18-23. ... In the early days of vaccine manufacture, significant variations in the efficacy of different batches of the same vaccine were ...

*DTaP-IPV-HepB vaccine

... is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis ... This vaccine article is a stub. You can help Wikipedia by expanding it.. *v ... "DTaP-IPV-HepB vaccine" - news · newspapers · books · scholar · JSTOR (June 2018) (Learn how and when to remove this template ... "Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance ...

*Paul Offit

Offit, Paul A. (2005). The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. Yale ... He was opposed by vaccine critics, many of whom believe vaccines cause autism, a belief that has been rejected by major medical ... doi:10.1016/j.vaccine.2014.04.085. PMID 24814559.. *^ a b "Author royalties from autism book donated to autism research" (Press ... Sabin Gold Medal from the Sabin Vaccine Institute in Washington, DC for his work on the oral rotavirus vaccine and his ...

*Maurice Hilleman

He cultivated material from her, and used it as the basis of a mumps vaccine. The Jeryl Lynn strain of the mumps vaccine is ... Hilleman was one of the early vaccine pioneers to warn about the possibility that simian viruses might contaminate vaccines.[8] ... The contamination actually occurred in both vaccines at very low levels, but because the oral vaccine was ingested rather than ... Of the 14 vaccines routinely recommended in current vaccine schedules, he developed eight: those for measles, mumps, hepatitis ...

*Scarlet fever

Ellis, Ronald W.; Brodeur, Bernard R. (2012). New Bacterial Vaccines. Springer Science & Business Media. p. 158. ISBN ... The vaccine approach has more potential to do so since vaccine formulations can target multiple subtypes of the bacteria.[13] A ... There have been several attempts to create a vaccine in the past few decades. These vaccines, which are still in the ... There used to be a diphtheria scarlet fever vaccine.[35] It was, however, found not to be effective.[36] This product was ...

*George Siber bibliography

Bacterial Vaccines. New York: Praeger, 1987. Siber GR. Special Lecture: importance of IgG subclasses and genetic factors in ... "Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults". Vaccine. 25 (33): 6164-6. doi:10.1016/j.vaccine ... Vaccine-type and non-vaccine type pneumococci after administration of 9valent CRM 197 conjugate pneumococcal vaccine (Pnc CRM9 ... Human hyperimmune globulins for bacterial infections in high-risk children. In: Cryz SJ, eds. Vaccines and Immunotherapy. New ...

*腦膜炎 - 維基百科,自由的百科全書

Vaccines against bacterial meningitis (PDF). British Medical Bulletin. 2004, 72 (1): 65-81. PMID 15802609. doi:10.1093/bmb/ ... 用肺炎球菌聯合疫苗(英語:Pneumococcal conjugate vaccine)(PCV)--一種能預防這種病原中七種常見血清的疫苗--對肺炎鏈球菌進行常規預防接種,能大大降低肺炎球菌性腦膜炎的發病率。[43][50]能涵蓋23株球菌的肺炎球菌多 ... EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force

*Scarlet fever

Ellis, Ronald W.; Brodeur, Bernard R. (2012). New Bacterial Vaccines. Springer Science & Business Media. p. 158. ISBN ... The vaccine approach has a greater likelihood of effectively preventing group A streptococcal infections because vaccine ... There have been several attempts to create a vaccine in the past few decades. These vaccines, which are still in the ... A vaccine developed by George and Gladys Dick in 1924 was discontinued due to poor efficacy and the introduction of antibiotics ...

*Conjunctivitis

Bacterial[edit]. The most common causes of acute bacterial conjunctivitis are Staphylococcus aureus, Streptococcus pneumoniae, ... 2015). Epidemiology and Prevention of Vaccine-Preventable Diseases. U.S. Dept. of Health & Human Services, Centers for Disease ... Bacterial[edit]. Bacterial conjunctivitis usually resolves without treatment.[11] Topical antibiotics may be needed only if no ... If bacterial conjunctivitis is suspected, but no response to topical antibiotics is seen, swabs for bacterial culture should be ...

*Dlawer Ala'Aldeen

From 1988 to 2014, Ala'Aldeen has worked on pathogenesis, molecular epidemiology and vaccine development of various bacterial ... Patent US6861507 - Screening of neisserial vaccine candidates and vaccines against pathogenic ... - Google Patents ... Molecular and Clinical Aspects of Bacterial Vaccine Development; and Medical Microbiology. He also holds patents for anti- ... Campylobacter agents and meningococcal vaccine candidates.[18] He was chairman or member of a number of National learned ...

*Rino Rappuoli

... conjugate vaccine against meningococcal-C disease and the first recombinant bacterial vaccine against pertussis. Currently,[ ... Rappuoli joined Chiron as head of European vaccines research in 1992 with the acquisition of Italian vaccines company Sclavo ... Rappuoli, was previously the Global Head of Vaccines Research for Novartis Vaccines & Diagnostics (Siena, Italy) Since 2015, Dr ... Rappuoli, Rino (2001). "Reverse vaccinology, a genome-based approach to vaccine development". Vaccine. 19 (17-19): 2688-2691. ...

*Emil von Behring

nobelprize.org Hewlett, Richard Tanner (1903). Serum therapy: bacterial therapeutics and vaccines. p. 3. Morton A. Meyers, M.D ...

*Extrachromosomal DNA

Circular bacterial plasmids are also the basis for the production of DNA vaccines. Plasmid DNA vaccines are genetically ... Bacterial plasmids are typically short sequences, consisting of 1 kilobase (kb) to a few hundred kb segments, and contain an ... Circular bacterial plasmids are classified according to the special functions that the genes encoded on the plasmid provide. ... Bacterial plasmids can also function in pigment production, nitrogen fixation and the resistance to heavy metals in those ...

*Amoebiasis

There is no vaccine. There are two treatment options depending on the location of the infection. Amoebiasis in tissues is ... Bacterial colitis can result in similar symptoms. Prevention of amoebiasis is by improved sanitation, including separating food ... In fact, most traveler's diarrhea is bacterial or viral in origin. With colonoscopy it is possible to detect small ulcers of ...

*Neisseria meningitidis

"FDA approves new combination vaccine that protects children against two bacterial diseases" (Press release). FDA. 14 June 2012. ... The first conjugate vaccine was licensed in 2005, the second in 2010. Conjugate vaccines are the preferred vaccine for people 2 ... "Vaccine. 27 (Suppl 2): B71-7. doi:10.1016/j.vaccine.2009.04.070. PMC 2712446 . PMID 19477055.. ... Some of the vaccines cover serogroup B, while others cover A, C, W, and Y.[26] A meningococcal polysaccharide vaccine (MPSV4) ...

*Streptococcus pneumoniae

Vaccine[edit]. Main article: Pneumococcal vaccine. Due to the importance of disease caused by S. pneumoniae, several vaccines ... Natural bacterial transformation involves the transfer of DNA from one bacterium to another through the surrounding medium. ... "Pneumococcal vaccines WHO position paper--2012" (PDF). Wkly Epidemiol Rec. 87 (14): 129-44. Apr 6, 2012. PMID 24340399.. ... "Children to be given new vaccine". BBC News. 8 February 2006.. *^ "Pneumococcal Vaccination: Information for Health Care ...

*Theobald Smith

After two years of work studying the efficacy of bacterial vaccination in pigs, Smith erroneously believed he had found the ... Brucellosis infections Used toxin/antitoxin as a vaccine for diphtheria (1909). In the process of investigating an epidemic of ... Smith also discovered the bacterial species which would eventually form the genus Salmonella. ... Variation and bacterial pathogenesis (1900). Discovered anaphylaxis (1903), which is also sometimes referred to as "Theobald ...

*Shigellosis

Currently, no licensed vaccine targeting Shigella exists. Several vaccine candidates for Shigella are in various stages of ... Shigellosis is a type of diarrhea caused by a bacterial infection with Shigella. Symptoms generally start one to two days after ... "Vaccine Research And Development: New strategies for accelerating Shigella vaccine development" (PDF). Weekly Epidemiological ... Mani, Sachin; Wierzba, Thomas; Walker, Richard I. (2016). "Status of vaccine research and development for Shigella". Vaccine. ...

*TA-CD

Scientific American Mind: Cocaine Vaccine Would you vaccinate your child against cocaine? A thermostable bacterial cocaine ... The vaccine does not affect the users "desire" for cocaine, only the physical effects of the drug. Phase III Clinical Trials ... This vaccine does not have any effect on the underlying neurobiological cause of addiction which a possible explanation for the ... TA-CD is an active vaccine developed by the Xenova Group which is used to negate the effects of cocaine, making it suitable for ...

*Minimum inhibitory concentration

in: VL Yu, G Edwards, PS McKinnon, C Peloquin, G Morse (Eds.) Antimicrobial therapy and vaccines, volume II: antimicrobial ... Pharmokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. ...

*Helicobacter cholecystus

Vaccines for Biodefense and Emerging and Neglected Diseases. Access Online via Elsevier, 2009. Chan, Voon Loong. "Bacterial ... Pathogenesis of bacterial infections in animals. Wiley. com, 2008. Helicobacter cholecystus at the Encyclopedia of Life LPSN. ...

*Tamas Bartfai

... ethical committees for vaccine programmes; bacterial vaccine development and distribution efforts; and landmine issues and the ... vaccine that is part of the current triple vaccine. Briefly, they cloned the pertussis toxin, mapped the antigenic epitopes ... This model is now used to produce other safe acellular vaccines. They also showed that 'toxoidation' of whole bacteria with ... using antibodies from individuals, who had the disease and or were vaccinated with the old whole-cell vaccine, and attached ...

*Typhus

A vaccine has been in development for scrub typhus known as the scrub typhus vaccine. The American Public Health Association ... They are caused by specific types of bacterial infection. Epidemic typhus is due to Rickettsia prowazekii spread by body lice, ... The first typhus vaccine was developed by the Polish zoologist Rudolf Weigl in the period between the two world wars. Better, ... Vaccines: A Biography. Springer 2010, p. 250 David G. Rempel. A Mennonite Family in Tsarist Russia and the Soviet Union, 1789- ...

*Antigenic escape

In order to fix this problem, vaccines must be able to cover the wide variety of strains within a bacterial population. In ... While vaccines are created to strengthen the immune response to pathogens, in many cases these vaccines are not able to cover ... The problem of antigenic escape has greatly deterred the process of creating new vaccines. Because vaccines generally cover a ... Recent research on many vaccines, including the malaria vaccine, has focused on how to anticipate this diversity and create ...

*Pneumococcal Awareness Council of Experts

As the three leading causes of bacterial meningitis in childhood are vaccine preventable, the regular use of conjugate vaccines ... Sequelae Due to Bacterial Meningitis among African Children: A Systematic Literature Review, and Bacterial Infections in ... is a project of the Sabin Vaccine Institute and is composed of global experts in infectious diseases and vaccines. Established ... "Bacterial Infections in Persons with Sickle Cell Disease: A Review of Data from Africa with a Focus on Pneumococcal Disease" " ...

*Genetically modified tomato

... has been introduced into tomato plants and in vivo studies show significant resistance to bacterial wilt and bacterial spot.[27 ... Vaccines[edit]. Tomatoes (along with potatoes, bananas and other plants) are being investigated as vehicles for delivering ... In 2000, the concentration of pro-vitamin A was increased by adding a bacterial gene encoding phytoene desaturase, although the ... Goyal, R.; Ramachandran, R.; Goyal, P.; Sharma, V. (2007). "Edible vaccines: Current status and future". Indian Journal of ...

*Streptococcal pharyngitis

There is no vaccine for the disease. Treatment with antibiotics is only recommended in those with a confirmed diagnosis. Those ... Strep throat is a common bacterial infection in children. It is the cause of 15-40% of sore throats among children and 5-15% ...
New York, US, October 26, 2019 As Creative Biolabs, a leading custom service provider in the field of vaccine development, releases bacterial vaccine development services forbacterial diseases.. Bacterial infectious diseases are the most common diseases that seriously endanger human health. Traditionally, the antibacterial drugs are the main force to treat bacterial diseases but drug abuse also brings the rapid increase of drug-resistant bacteria, leading to less effective control of infections. Therefore, the bacterial vaccines that can improve the resistance of susceptible population to pathogens and reduce the incidence of pathogen infection have become a hot topic in vaccine development field.. Supported by the continuous progress of immunology, molecular biology and other sciences, Creative Biolabs is able to stand on the shoulders of giants to provide global clients with various bacterial vaccines development services, which can be customized according to the specific requirements of ...
Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines, Immunomodulators available in on Powells.com, also read synopsis and reviews.
This newly started bacterial vaccine research group is looking for a motivated scientist, who loves challenges, to evaluate the immunogenicity and efficacy of potential vaccine candidates. The role requires knowledge of immunological techniques such as T cell ELISPOT, proliferation assays, cytokine measurements, intercellular cytokine staining, FACS analysis and cell culturing.. The scientist will be responsible for the development of assays to measure immune responses of various bacterial vaccine candidates. The focus will be on T cell responses (Th1, Th2, Treg), cytokine induction and proliferation assays, intercellular cytokine staining and FACS analysis. ...
Merck has teamed up with 4D pharma to develop bacterial strains as vaccines. The deal gives Merck the chance to pick up three candidates against undisclosed
Diagnosis Code T50.A96A information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Diagnosis Code T50.A92A information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
La cookies nos permiten mejorar la experiencia de navegación. Al continuar con la navegación entendemos que acepta nuestra política de cookies.Acepto Más información ...
Informasi yang diungkapkan: visi, misi, sasaran usaha dan strategi Perusahaan, kondisi keuangan, susunan dan kompensasi pengurus, Pemegang Saham Pengendali, kepemilikan saham oleh anggota Direksi dan anggota Dewan Komisaris beserta anggota keluarganya dalam Perusahaan dan Perusahaan lainnya, sistem manajemen risiko, sistem pengawasan dan pengendalian internal, sistem dan pelaksanaan GCG serta tingkat kepatuhannya, dan kejadian penting yang dapat mempengaruhi kondisi Perusahaan ...
...Researchers from Southern Medical University in Guangdong Guangzhou ...The investigators constructed a live recombinant bacterial vaccine ex...The vaccine elicited specific anti-Hp0410 IgG antibodies in serum and... H. pylori is a class 1 human carcinogen according to the World...,H.,pylori,vaccine,shows,promise,in,mouse,studies,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Patients will initially receive three priming CpG-MCL vaccinations in 21 days at 4-7 day intervals, followed by collection of primed T-Cells. Subsequently, within 72 hours of autologous hematopoetic cell transplant (AHCT)(standard of care procedure), the patient will receive his/her CpG-MCL vaccine and reinfusion of primed T cells (immunotransplant). At ,/= 3 months after AHCT, when medically feasible, the patient will receive the final CpG-MCL vaccine. Regular follow-up research analysis of molecular residual disease will continue for 3 years or until disease progression ...
Escherichia, Escherichia Coli, Proteins, Salmonella, Salmonella Enterica, Arabinose, Carbon, D-glucose, Antigens, Bacterial Vaccine, Disease, Epitopes, Food, Food-borne Disease, Humans, Hybrid, Procedure, Protein Translocation, Staphylococcus, Vaccines
Formulation of a live bacterial vaccine for stable room temperature storage results in loss of acid, bile and bile salt resistance
Improved remission rate and duration in nodular non-Hodgkin lymphoma (NNHL) with the use of mixed bacterial vaccine (MBV). American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 1981 ...
Head of Bacterial portfolio Clinical read-out development. (Since June 2010). Heading a team of two Project Managers. The mission of the team: Select appropriate assays for evaluation of bacterial vaccine. Ensure development of assays as well as routine testing in due time. Scientific and operational lead of a multidisciplinary team devoted to clinical read-outs Establish strategies for regulatory submission/discussion. Interact with internal and external experts (KOL, regulatory agencies, . ) Former ...
In addition to modern antigen-specific antibody- and vaccine-based immunologic cancer therapies, "nonspecific" immunotherapies with bacterial products have also shown antitumor effects (24-26). Over the past 2 decades, immunologic research has broadened our understanding of how these bacterial products may stimulate the immune system, and how endogenous mediators, induced by nonspecific immune stimulation influence the immune defense (22, 27, 28). In previous studies with MBV, also known as Coleys toxins, fever induction has been considered to be the key indicative aspect of successful treatment (29). However, there has been no systematic investigation of the mechanism by which MBV-induced fever would contribute to mediate tumor regression.. Therefore, a primary objective of our study was to identify the dose of standardized MBV that increased the body temperature from 38°C to 39.5°C. Eleven of 12 patients developed fever of ≥38°C at a given MBV dose level. The pyrogenic dose level varied ...
Free, official coding info for 2018 ICD-10-CM T50.A92A - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
It has been nearly 20 years since the first Phase I clinical trial of a live-attenuated bacterial vaccine was created by recombinant DNA methods, opening the door to the use of these organisms as mucosal delivery vehicles for passenger antigens. Over this time, a number of animal studies have indicated the feasibility of this approach. These include studies showing that bacteria can deliver antigens expressed by the bacterium itself and that bacteria can deliver DNA vaccines to be expressed in target eukaryotic cells. Concomitant studies have identified a number of attenuating mutations that render the bacterial vectors both safe and immunogenic in humans. Both avenues of research indicate the significant promise of this approach to mucosal vaccine development; however, this promise remains largely unrealized at the level of human clinical trials. This review sketches the history of this problem and points toward possible solutions using Salmonella vaccine vectors as the prototypes.
On tonights 5:30 p.m. WJLA-TV7 (ABC) News in Washington, D.C., Vicky Debold, PhD, RN speaks out about how her son regressed into autism after his 15 month vaccinations. Vickys son, who received 7 live virus and killed bacterial vaccines on one day in 1998, suffered nearly identical reactions as the daughter of Dr. and Mrs. Poling. During the interview, she said, "I did something stupid. I gave my son 7 vaccines on one day. " She went on to say "I regret this but I cant take it back." Like Terry Poling, who was formerly a pediatric intensive care nurse, Dr. Debold recalls that she was a pediatric ICU nurse and completely trusted the vaccine recommendations by the CDC and AAP. Both Terry and Vicky fully vaccinated their children. Vicky, who is on NVICs Board, has served as NVICs Director of Patient Safety for the past few years and has counseled many parents reporting vaccine reactions and regression into poor health to NVIC during the past few years. (View some of these reaction reports at ...
Summary of Facts and Submissions. I. European patent No. 0 790 835 (application No. 95939926.2, published as WO-A-96/14087) was granted with 8 claims. The patent relates to specific immunotherapy of cancer using a live recombinant bacterial vaccine vector.. II. Notice of opposition was filed by the opponent requesting the revocation of the European patent on the grounds of Article 100(a), (b) and (c) EPC. The opposition division revoked the patent on the grounds that the main and the auxiliary requests then on file did not fulfil the requirements of Article 56 EPC.. III. The opposition division considered the teaching of document D3 as the closest prior art. In its opinion, the problem underlying the patent in suit, namely the provision of an alternative tumour vaccine (main request) or the provision of an improved tumour vaccine (auxiliary request) had not been solved in an inventive manner.. IV. The patentee (appellant) filed an appeal against the decision of the opposition division.. V. In a ...
According to Minutes of the 15th Session (November 20-21, 1975) of the Panel of Review of Bacterial Vaccines and Toxoids with Standards and Potency (data presented by the US Bureau of Biologics, and the FDA):For several reasons, diphtheria toxoid, fluid or absorbed, is not as effective an immunizing agent as might be anticipated. Clinical (symptomatic) diphtheria may occur . . . in immunized individuals--even those whose immunization is reported as complete by recommended regimes . . . the permanence of immunity induced by the toxoid . . . is open to question.Medics have always known this vaccine doesnt work and have been writing about it since it was invented. For instance, in the Practitioner, April 1896, it was written that the serum did not, to any appreciable degree, prevent the extension of the disease to the larynx; all the severe cases died, and the good result in the lighter ones was attributable to the mild type of the epidemic." The doctor also states that, at the Hospital of ...
The company PHARMAGAL- BIO Ltd., established in 1998 in Nitra, is the only significant Slovak manufacturer of veterinary immunological medicaments. Modern and dynamic company specialises in research, development and manufacture of virus and bacterial vaccines, diagnostic tests, development of method for complex preventive programmes for economically important categories of domestic animals.. Our mission is to enhance the quality and welfare of animals, which will allow maximal utilization of their production potential. Vaccines produced by our company cover immunoprophylaxy of majority of the most important infectious diseases.. We are stable, correct and reliable business partner. We do work in more than twenty countries. We aim at distributional and manufacturing companies with intention to co-operate in the field of development, registration, commercial realization and contractual manufacture. We keep up with the times, we apprehend new trends in research, technologies and trade. We are ...
New Scientist News - Make mine a zombie vaccine: Zombie bacteria have been created that could be used to make more stable vaccines.Traditionally, vaccines use either attenuated live bacteria, grown in conditions that disable their virulent properties, or killed bacteria. Attenuated live vaccines promote a strong immune response, but can be difficult to store and…
Advances in genomics and innovative strategies such as reverse vaccinology have changed the concepts and approaches to vaccine candidate selection and design. Genome mining and blind selection of novel antigens provide a novel route to investigate the mechanisms that underpin pathogenesis. The resulting lists of novel candidates are revealing new aspects of pathogenesis of target organisms, which in turn drives the rational design of optimal vaccine antigens. Here we use the discovery, characterization, and exploitation of fHbp, a vaccine candidate and key virulence factor of meningococcus, as an illustrative case in point. Applying genomic approaches to study both the pathogen and host will ultimately increase our fundamental understanding of pathogen biology, mechanisms responsible for the development of protective immunity, and guide next-generation vaccine design ...
Leading structural frame engineering specialist, B &amp; K Structures Ltd, of Derby, has won another Gold Medal award in the prestigious RoSPA Occupational Health and Safety Awards 2011. The Royal Society for the Prevention of Accidents (RoSPA), a ...
The coronavirus pandemic has set off an unprecedented global scramble for a vaccine. There are more than 100 potential vaccine candidates, according to the World Health Organization, but only eight have entered the crucial clinical trials stage. Four are in the United States and Europe, with the rest in China.
Oral vaccines which are intended for global use do not necessarily induce the same immune responses in all children worldwide. In fact, several vaccines often induce less frequent and lower mean antib
This publication describes methods used to increase the effectiveness of modified live vaccines, including proper storage, handling, and administration.
RoSPA can approve your organisations internal health and safety training courses, giving you peace of mind and delegates increased confidence.
5-22-17For the longest time, Ive wondered why scientists have not done morestraightforward, direct comparisons of the health outcomes of vaccinated children versus those whose parents have chos...read more
Looking for online definition of polyvalent pneumococcal vaccine in the Medical Dictionary? polyvalent pneumococcal vaccine explanation free. What is polyvalent pneumococcal vaccine? Meaning of polyvalent pneumococcal vaccine medical term. What does polyvalent pneumococcal vaccine mean?
Recognition of bacteria by PRRs is a fundamental aspect of the innate immune response to pathogens. Impaired recognition can lead to severe illness and death. For example, mutations or TLR polymorphisms that affect the interaction of TLR with either agonists or signaling proteins have been associated with greatly increased susceptibility to infection in humans (reviewed in reference 59). We demonstrated previously that F. tularensis LVS is specifically recognized by TLR2 in HEK293T/TLR2 transfectants and in murine DC (8, 30) and that F. tularensis LVS infection induces in mice or their macrophages a very strong proinflammatory response as measured at the level of gene and protein expression (8). Thus, our demonstration herein that signaling through TLR2 is an obligatory component of the early macrophage response to F. tularensis LVS infection (Fig. 1) represents a key step forward in unraveling the potent proinflammatory response induced by this bacterium.. F. tularensis is an intracellular ...
Author Summary Conventional treatment of bacterial infections typically includes administration of antibiotics. However, many pathogens have developed spontaneous resistance to commonly used antibiotics. Development of new compounds that stimulate the host immune system to directly kill bacteria by mechanisms different from those utilized by antibiotics may serve as effective alternatives to antibiotic therapy. In this report, we describe a novel compound capable of controlling infections mediated by different, unrelated bacteria via the induction of host derived reactive oxygen and reactive nitrogen species. This compound is comprised of cationic liposome DNA complexes (CLDC) and crude membrane preparations (MPF) obtained from attenuated Francisella tularensis Live Vaccine Strain (LVS). Pretreatment of primary mouse or human cells limited replication of virulent F. tularensis, Burkholderia pseudomallei, Yersinia pestis and Brucella abortus in vitro. CLDC+MPF was also effective for controlling lethal
Included studies compared injectable pneumococcal vaccines (polysaccharide, conjugate, or other type) with control (placebo or no vaccine) or another pneumococcal vaccine in adults with COPD. Primary outcomes were pneumonia, all-cause and respiratory-related mortality, and use of health care. Other outcomes included acute COPD exacerbation ...
Immunization(vaccination) can be discrete as active immunity formed by vaccine. It is resistance and immunologic retention corresponding to natural infection but deprived of risk of sickness. There are two rudimentary categories of vaccines: live attenuated and inactivated. Live attenuated vaccines are produced by altering a disease-producing virus or bacterium in a research laboratory. Vaccines derived from bacterium is called as bacterial vaccine and from virus is as viral vaccine. The subsequent vaccine organism retains the ability to duplicate and produce immunity, but generally does not cause illness. Inactivated vaccines can be self-possessed either by whole viruses or bacteria, or portions of either.. ...
Sigma-Aldrich offers abstracts and full-text articles by [Lenka Plzakova, Klara Kubelkova, Zuzana Krocova, Lenka Zarybnicka, Zuzana Sinkorova, Ales Macela].
Elkins, Karen L., Catharine M. Bosio, and Tonya R. Rhinehart-Jones. "Importance of B cells, but Not Specific Antibodies, in Primary and Secondary Protective Immunity to the Intracellular BacteriumFrancisella tularensis Live Vaccine Strain ." Infection and Immunity 67.11 (1999): 6002-6007. Web. 28 Mar. 2020. ...
Wim Jiskoot graduated as a pharmacist in 1987 and received his PhD degree in 1991 at Utrecht University on pharmaceutical aspects of monoclonal antibodies. As a postdoctoral fellow at the University of Utah (1991-1993) he studied protein-ligand interactions using biophysical techniques. From 1994-1998 he was head of the Department of Bacterial Vaccine Development at the National Institute of Public Health and the Environment (RIVM), Bilthoven. In 1998 he became a staff member at the Department of Pharmaceutics, Utrecht University, where he focused his research on formulation and physicochemical characterization of therapeutic proteins and vaccines. In March 2006 he was appointed as full professor at the Division of Drug Delivery Technology, LACDR, and as the coordinator of the Biologics Research Platform Leiden (BRPL). His current research is concentrated on two themes: (1) formulation and unwanted immunogenicity of therapeutic proteins and (2) vaccine delivery.. ...
Wim Jiskoot graduated as a pharmacist in 1987 and received his PhD degree in 1991 at Utrecht University on pharmaceutical aspects of monoclonal antibodies. As a postdoctoral fellow at the University of Utah (1991-1993) he studied protein-ligand interactions using biophysical techniques. From 1994-1998 he was head of the Department of Bacterial Vaccine Development at the National Institute of Public Health and the Environment (RIVM), Bilthoven. In 1998 he became a staff member at the Department of Pharmaceutics, Utrecht University, where he focused his research on formulation and physicochemical characterization of therapeutic proteins and vaccines. In March 2006 he was appointed as full professor at the Division of Drug Delivery Technology, LACDR, and as the coordinator of the Biologics Research Platform Leiden (BRPL). His current research is concentrated on two themes: (1) formulation and unwanted immunogenicity of therapeutic proteins and (2) vaccine delivery.. ...
According to a study published in the journal Pediatrics, vaccinating mothers against pertussis, or whooping cough, is highly protective for the infants during the first months of life, and continued to offer additional protection even after the childhood vaccine schedule began. Learn more. ...
Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches. In an effort to overcome limitations of immunostimulatory cancer vaccines, Gradalis has designed a novel autologous vaccine to address inability to fully identify cancer associated antigens, antigen recognition by the immune system (i.e. antigen--,immunogen), effector potency, and cancer-induced resistance. In an effort to overcome limitations of immunostimulatory cancer vaccines, we designed a novel dual-modulatory autologous whole cell vaccine, Vigil™, incorporating the rhGMCSF transgene and the bifunctional shRNAfurin (to block proprotein conversion to active TGFb1 and b2) to 1) address the inability to fully identify cancer associated antigens, 2) effect antigen recognition by the immune system, 3) enhance effector potency, and 4) subvert endogenous cancer-induced immune resistance. We have also completed the Phase I assessment ...
FDA Collaboration Seeks to Speed Development of Pneumococcal Vaccines for Children in Developing CountriesPATH supports FDA advancement of a key step in vaccine development The U.S. Food and Drug
Yes, you can take multiple vaccines at one time. There is a caveat for those that are HIV-infected. Live vaccines (such as MMR - measles, mumps, rubella) may not be such a good idea if CD4 count is...
One of the most important components of your pets wellness care is keeping his/her vaccines up-to-date. Familiarize yourself with the different vaccines that we recommend for dogs and cats.
Macam mana ia merebak? Dari udara contohnya batuk dan juga sentuhan dari orang yg sihat yang membawa bakteria tersebut. Biasanya kanak-kanak yang duduk dekat taska adalah amat digalakkan ambil vaccine ni ...
Available in the form of a shot, the pneumonia vaccine can help prevent this disease in people at risk. As this eMedTV resource explains, a few different vaccines are available, and this article describes one of these vaccines in more detail.
MINNEAPOLIS - The U.S. Department of Agriculture is working on a vaccine to counter a deadly strain of bird flu, as losses to poultry producers mount.
In this case study, streamlined print management improved user-to-device ratios, increased sustainability and gave better protection of confidential documents.
lyme disease vaccine - MedHelps lyme disease vaccine Center for Information, Symptoms, Resources, Treatments and Tools for lyme disease vaccine. Find lyme disease vaccine information, treatments for lyme disease vaccine and lyme disease vaccine symptoms.
Francisella tularensis, the causative agent of tularemia, is one of the most infectious human bacterial pathogens. It is phagocytosed by immune cells, such as monocytes and macrophages. The precise mechanisms that initiate bacterial uptake have not yet been elucidated. Participation of C3, CR3, class A scavenger receptors and mannose receptor in bacterial uptake have been already reported. However, contribution of an additional, as-yet-unidentified receptor for F. tularensis internalization has been suggested. We show here that cell-surface expressed nucleolin is a receptor for Francisella tularensis Live Vaccine Strain (LVS) and promotes LVS binding and infection of human monocyte-like THP-1 cells. The HB-19 pseudopeptide that binds specifically carboxy-terminal RGG domain of nucleolin inhibits LVS binding and infection of monocyte-like THP-1 cells. In a pull-down assay, elongation factor Tu (EF-Tu), a GTP-binding protein involved in protein translation, usually found in cytoplasm, was recovered among
The present uncertainty of which live viral or bacterial vaccines can be given to immunodeficient patients and the growing neglect of societal adherence to routine immunizations has prompted the Medical Advisory Committee of the Immune Deficiency Foundation to issue recommendations based on published literature and the collective experience of the committee members. These recommendations address the concern for immunodeficient patients acquiring infections from healthy subjects who have not been immunized or who are shedding live vaccine-derived viral or bacterial organisms. Such transmission of infectious agents can occur within the hospital, clinic, or home or at any public gathering. Collectively, we define this type of transmission as close-contact spread of infectious disease that is particularly relevant in patients with impaired immunity who might have an infection when exposed to subjects carrying vaccine-preventable infectious diseases or who have recently received a live vaccine. ...
According to the latest market report published by Credence Research, Inc. "Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025" the global recombinant vaccines market is expanding at a CAGR of 6.4% from 2017 to 2025.. Browse the full report Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 report at http://www.credenceresearch.com/report/recombinant-vaccines-market. Market Insights. Recombinant vaccines are third generation vaccines, produced by using genetic engineering or recombinant DNA technology. It is expected that the global recombinant vaccines market will demonstrate lucrative market growth during the forecast period as these vaccines are more advanced as against the conventional alternatives. Expected launch of recombinant vaccines such as VPM1002 (BCG), EBOV-GP (ebola), Shingrix (herpes zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF etc. (prostate cancer) would ...
SUMMARY: In the assessment of immunity to the encapsulated virulent strain of Klebsiella pneumoniae and as avirulent mutant defective for capsular polysaccharide (CPS), killed bacterial vaccine of both strains could protect mice equally against challenge with 100 x LD50 of encapsulated wild strain. Antisera to each strain conferred the same level of protection on naive mice upon transfer; the protective anti-mutant serum was highly capable of opsonizing the encapsulated bacteria. In addition to the common antigenic components shared by both strains, the wild strain had antigen(s) unrelated to the mutant since the protective capacity of the anti-wild serum was not affected by preabsorption with the mutant strain; the protection conferred by the anti-mutant serum was mediated by antibodies against non-capsular antigens since the antiserum did not contain antibodies against purified CPS detectable by ELISA. As possible candidates among the non-capsular antigens, outer-membrane proteins (OMPs) extracted
[117 Pages Report] Check for Discount on Japan Varicella Attenuated Live Vaccine Market Report 2016 report by QYResearch Group. Notes: Sales, means the sales volume of Varicella Attenuated Live...
Research Report on United States Varicella Attenuated Live Vaccine Market Report 2017. The Report includes market price, demand, trends, size, Share, Growth, Forecast, Analysis & Overview.
Immunization during pregnancy, that is the administration of a vaccine to a pregnant woman, is not a routine event as it is generally preferred to administer vaccines either prior to conception or in the postpartum period. When widespread vaccination is used, the risk for an unvaccinated pregnant patient to be exposed to a related infection is low, allowing for postponement, in general, of routine vaccinations to the postpartum period. Nevertheless, immunization during pregnancy may occur either inadvertently, or be indicated in a special situation, when it appears prudent to reduce the risk of a specific disease for a potentially exposed pregnant woman or her fetus. As a rule of thumb the vaccination with live virus or bacteria is contraindicated in pregnancy. BCG vaccine is used against tuberculosis and is contraindicated in pregnancy. Inactivated bacterial vaccine is used during pregnancy for women who have a specific risk of exposure and disease. Vaccination against pneumococcus or ...
What are lyme disease vaccine side effects for dogs? Learn the answer to this Ask A Vet question from the pet health experts at Banfield Pet Hospital.
Experimental Vaccines will expose the truths on Health & Science Vaccines. We will use the following guidelines The Trivium of knowledge
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the...
H1N1 Swine influenza and pneumonia syndrome death, CDC urging pneumococcal vaccine, containing toxic phenol, studies show says pneumonia vaccine doesnt work ...read more NOW
While formal conclusions regarding autisms causes have yet to be drawn, many researchers today believe autism occurs as the result of genetic and other predispositions coupled with environmental factors or triggers. Of the possible environmental components involved, the most heated debates have arisen over the possibility that vaccines play a critical role in the development of autism in susceptible individuals.. There is no dispute that the number of vaccines given to infants and young children has risen dramatically over the past few decades, as has the rate of autism diagnoses among children in the U.S.[i] [ii] During the past 25 years, the number of vaccines given to children by the age of six has more than doubled, with todays schedule requiring that 48 doses of 14 different vaccines be given to kids before they reach the first grade. [iii] The Centers for Disease Control and Prevention (CDC) currently puts autism rates at one in 88, and the American Academy of Pediatrics reported in 2004 ...
Care guide for Pneumococcal Vaccine For Children (Ambulatory Care). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Synbiosis, a world-leading manufacturer of automated microbiological systems, is pleased to announce its ProtoCOL automated colony counter offers new features to guarantee the fastest, most accurate testing of pneumococcal vaccines using an OPKA assay.
Scientists have developed a novel vaccine candidate that may prevent HIV infection by stimulating an immune response against sugars that form a protective shield around the virus.
Merck has realigned the positions of some of its top division chiefs as it focuses on several areas, especially the development of vaccines. Margaret McGlynn is being hustled into the presidents spot of Merck Vaccines as the drug giant spurs the development of four late-stage vaccines. CFO Judy Lewent will also take on additional responsibilities in strategic planning. - read this report from Newsday for more
Free resource for searching and exporting immune epitopes. Includes more than 95% of all published infectious disease, allergy, autoimmune, and transplant epitope data.
Healthy children who have not finished vaccination by age 2 should get one dose. Children with certain chronic diseases may need additional doses between the ages of 2 and 6. Children who began immunization with the older PCV7 vaccine can continue the series using PCV13.. ...
Nothing ruins a nice cruise or a gluttonous run down the office party buffet like the norovirus. The obnoxious virus causes the euphemistically-named
Millions of dollars have been invested to deliver to the livestock producer safe and efficacious vaccines. So it behooves us to handle these products in a manner that will maximize the immune response in the healthy animal, says John Kirkpatrick, DVM, and Oklahoma State University College of Veterinary Medicine professor emeritus.
An experimental vaccine against cervical cancer has cleared its final clinical hurdle, showing in a large trial of more than 12,000 women that it is 100% effective in blocking the major forms of the
Im not keen on vaccines for everyone. In America,we should be allowed to choose whether or not we wish to vaccinate ourselves and our children. All too often, and becoming more common, is the requirement for workers in the health care field to get vaccinated. For children, some schools wont allow attendance until vaccine requirements…
www.MOLUNA.de Vaccinology [4096282] - List of Contributors, viiinPreface, xiinPart 1 Introductionn1 Concept and Scope of Modern Vaccines, 3nD. Huw Davies, Clint S. Schmidt, & Nadeem A. SheikhnPart 2 Principles of Vaccine Designn2 Strategies to Stimulate Innate Immunity for Designing Effective Vaccine Adjuvants, 15nHeather L. Wilson, Scott Napper, George K. Mutwiri, Sylvia van Drunen Littel-van
In the absence of an efficacious vaccine and curative antiviral drugs against HIV-1, novel strategies are required to protect host CD4+ T-cells from the virus a...
I am trying to understand the correct use of these codes. Specifically, the descriptions state vaccine component and each additional vaccine component
H 845.1 I61b 2011 c.2 Intervals between Live Vaccines and Other Rules All vaccines can be administered simultaneously (on the same day). 2 Live Vaccines Live vaccines can be given on the same day. If they are not given on the same day, they should be separated by a minimum 4-week interval, because the immune response to one of the vaccines might be impaired. If two live vaccines are not given on the same day and are given less than four weeks apart, the second vaccine should be repeated. Alternatively, the effectiveness of the second vaccine can be checked by serologic testing. H Dont do this less than 4 weeks at least 4 weeks This applies to MMR, varicella, zoster, yellow fever vaccines & LAIV; but, it does not apply to oral typhoid and rotavirus vaccines. Inactivated vaccines do not interfere with live vaccines and live vaccines do not interfere with inactivated vaccines. An inactivated vaccine can be administered either simultaneously or at any time before or after a different inactivated or ...
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine: Infect.Immun.
Treatment of Tularemia is a rare infectious disease that can attack the skin, eyes and lungs. Fewer than 200 cases of tularemia are reported annually in the United States - mainly in western and south central states, Tularemia, often called rabbit fever or deerfly fever, is caused by the bacterium Francisella tularensis. The disease mainly affects animals, especially rodents, rabbits and hares, though it can also infect birds, reptiles and fish, Tularemia spreads to humans through several routes, including insect bites and direct exposure to an infected animal. Highly contagious and potentially fatal if not treated, tularemia has been identified as a possible bioweapon. If diagnosed early, doctors can usually treat tularemia effectively with antibiotics, but the goal is to eliminate tularemia, Tularemia, Tularemia Treatment, Cause Of Tularemia, Symptoms Of Tularemia, Tularemia Definition, Tularemia Diagnosis, Prevalence Of Tularemia, Tularemia Bacteria, Tularemia Disease, Tularemia Emedicine, Tularemia
Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin.
According to the latest market report published by Credence Research, Inc. "Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025" the global recombinant vaccines market is expanding at a CAGR of 6.4% from 2017 to 2025.. Browse the full report Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 report at http://www.credenceresearch.com/report/recombinant-vaccines-market. Market Insights. Recombinant vaccines are third generation vaccines, produced by using genetic engineering or recombinant DNA technology. It is expected that the global recombinant vaccines market will demonstrate lucrative market growth during the forecast period as these vaccines are more advanced as against the conventional alternatives. Expected launch of recombinant vaccines such as VPM1002 (BCG), EBOV-GP (ebola), Shingrix (herpes zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF etc. (prostate cancer) would ...
Global Varicella Attenuated Live Vaccine Market: This market research report focuses on Past-Current Size, Shares, Segment & Forecast to 2022.
Massis, LM et al. Anti-flagellin antibody responses elicited in mice orally immunized with attenuated Salmonella enterica serovar Typhimurium vaccine strains. Mem. Inst. Oswaldo Cruz, Sept 2008, vol.103, no.6, p.606-610. ISSN 0074- ...
Recognition from the world Health Organization (wHO) for polio vaccines (9 April 1997), measles 10 doses & 20 doses (9 April 1997 & 4 September 2006), Hepatitis B Uniject (13 May 2004), Oral Polio Vaccine Tipe 1/mOPV-1 monovalent (3 November 2009), Oral Polio Vaccine/bOPV bivalent (26 May 2010), bacterial vaccines (Diphtheria, Pertussis, Tetanus) (6 April 2011), Tetanus in vial form (11 March 1999) & Uniject (29 October 2003), Td (6 July 2011), DT (11 March 1999) and DTP-HB combination vaccine, have all passed the wHO prequalified test (7 October 2004), Pentabio (16 December 2014). ...
Glentham Life Sciences is a supplier of GM8712 - Adipic acid dihydrazide (1071-93-8). Find catalogue prices, chemical data, technical specifications and MSDS documents.
BACKGROUND: The bacterium Francisella tularensis is recognized for its virulence, infectivity, genetic homogeneity, and potential as a bioterrorism agent. Outbreaks of respiratory tularemia, caused by inhalation of this bacterium, are poorly understood. Such outbreaks are exceedingly rare, and F. tularensis is seldom recovered from clinical specimens.. METHODS: A localized outbreak of tularemia in Sweden was investigated. Sixty-seven humans contracted laboratory-verified respiratory tularemia. F. tularensis subspecies holarctica was isolated from the blood or pleural fluid of 10 individuals from July to September 2010. Using whole-genome sequencing and analysis of single-nucleotide polymorphisms (SNPs), outbreak isolates were compared with 110 archived global isolates.. RESULTS: There were 757 SNPs among the genomes of the 10 outbreak isolates and the 25 most closely related archival isolates (all from Sweden/Finland). Whole genomes of outbreak isolates were ,99.9% similar at the nucleotide ...
New Delhi: Pfizer has been granted an Indian patent for its Prevenar 13 - a pneumococcal vaccine. The vaccine costs more than Rs 3,000 per dose and the three doses required to immunise a child cost more than Rs 10,000. The decision of the patent office bars other Indian companies from making a cheaper version of the vaccine. Although the vaccine is exorbitantly expensive, it has poor efficacy. Yet one is not surprised by the news of the patent, given the background story, nationally and internationally, of this vaccine. According to the petition by Prashant Bhushan in the Delhi high court, this vaccine has the distinction of being recommended even before it was manufactured, let alone tested, by the National Technical Advisory Group on Immunization, which is meant to evaluate and recommend vaccines for introduction in the country.. Vaccine with little efficacy. Pneumococcal bacteria are only one of a very large number of organisms that cause pneumonia. There are many other bacteria, mycoplasma ...
The thesis of Gaurav Kanojia shows the application of spray drying technology to two viral vaccines and an experimental bacterial vaccine. The research was extended to stabilize monoclonal antibodies as well. Drying with stabilizing excipients was able to maintain the activity of the biopharmaceuticals and shows the potential of such biopharmaceuticals to be used without refrigeration in a powder form.. Maintaining vaccines and therapeutic proteins stable outside the cold chain remains a challenging ordeal. Spray drying is a promising technique to tackle this problem by providing dry powder formulations, with improved thermostability. In addition, powder particles can be engineered by spray drying to desired requirements, allowing them to be used by various delivery methods and routes. In this thesis Kanojia investigated the applicability of the spray drying technique to various biopharmaceuticals, including three vaccines and one monoclonal antibody. The work focuses on aspects such as the ...
Today is the last edition in Dr. Jennifer Coatess six part canine vaccination series. Today she talks about the Lyme disease vaccine.
Everything you need to know about the pneumococcal polysaccharide vaccine given to prevent diseases caused by pneumococcal bacteria, such as pneumonia, blood poisoning (septicaemia) and meningitis, including when pneumococcal vaccine is recommended and possible side effects
source: Avian Influenza Daily Digest Technorati Tags: Pneumococcal vaccine AI Research Pneumococcal vaccine could prevent numerous deaths, save costs during a flu pandemic, model predicts 10/29/08 Eureka Alert--A new predictive model shows that vaccinating infants with 7 valent pneumococcal conjugate vaccine (PCV7)--the current recommendation--not only saves lives and money during a normal flu season by…
Connie K. Ho for redOrbit.com - Your Universe Online. Scientists recently revealed that they plan to study the pneumococcal vaccines in older adults to determine if there´s a strong immune response due to a higher dosage of the vaccine. The study, funded by the National Institute of Health (NIH) as well as the National Institute of Allergy and Infectious Diseases, looked at a group of adults who previously received a vaccine that worked against pneumonia and other pneumococcal diseases.. In the study, the team of investigators will analyze two dosages of a pneumococcal vaccine that will be tested by 882 females and males who are between 55 to 74 years of age. The vaccine was approved for people of a range of ages; this includes children between six weeks and five years of age as well as adults who are 50 years of age can take the vaccine. Researchers believe that the study will help them understand how to strengthen the vaccines to better protect patients.. In the past, the vaccine PPSV23 ...
The Europe Pneumonia Vaccines Market would witness market growth of 4.5% CAGR during the forecast period (2019-2025).. Pneumococcal diseases are most common in younger children; however, adults and the elderly population are also prone to pneumococcal contaminations that lead to death as well. Pneumonia vaccines are primarily given to the children less than 2 years and to the adults of 65 years and older. These vaccines help to provide immunization against 13 types of pneumococcal bacteria that cause infection in the lungs. Increasing government support in creating awareness regarding pneumonia immunization programs, rising prevalence of pneumococcal contaminations within the population, and introduction of novel pneumococcal vaccines are some of the major factors driving the growth of the global pneumonia vaccine market. However, longer timelines required for the production of pneumococcal vaccines and higher costs associated with the development of the vaccines are hindering the growth of the ...
According to the National Institute of Allergy and Infectious Diseases website,. Live, Attenuated Vaccines contain a version of the living microbe that has been weakened in the lab so that it cant cause disease. There are some downsides to this type of vaccine and one is that the attenuated microbe in the vaccine could revert to a virulent form and cause disease. Question: Could this be the reason why those who are vaccinated against measles, whooping cough, and chickenpox are the very ones who are contracting these infectious diseases they supposedly are immunized against? So, why blame outbreaks on unvaccinated children when, in most cases, published data confirm the majority of those contracting these diseases are fully vaccinated children.. Inactivated Vaccines are those in which the disease-causing microbe has been inactivated with chemicals, heat, or radiation. According to the website, Most inactivated vaccines, however, stimulate a weaker immune system response than do live vaccines. ...
4) These studies are often misleading because they are usually sensitive to a few key assumptions and they normalize everything to a dollar value. Here is a sample problem with normalizing everything to a dollar value: let us imagine we have two different vaccines that we want to give to 1 million people. In the testing, 50% of the people suffered 3 days of mild illness causing missed work with no long term effects from vaccine A. 1 person died from vaccine B with no one else suffering any ill effects. The cost of vaccine A would be far higher in almost any financial model, and yet clearly we would much rather fall mildly ill for 3 days rather than risk a 1 in a million chance of dying.. This particular study is interesting in that it is not actually performing a cost comparison or justification. It is only trying to set the cost of a measles case and the cost of a measles vaccine reaction. In order to judge the likelihood of bias in a study, a quick check on the authors reveals that although ...
This thesis is about analyzing genetic differences among isolates of Francisella tularensis - the tularemia-causing bacterium. To elucidate how these bacterial isolates are related, and their geographical and genetic origins, I have developed typing assays for Francisella and used them to study the epidemiology of tularemia.. Tularemia is an infectious disease of humans and other mammals found throughout the Northern Hemisphere. The severity of the disease depends on the type of F. tularensis causing the infection. In Sweden, as in other countries of Europe and Eurasia, tularemia is caused by F. tularensis subsp. holarctica, while other varieties of the bacterium occur in Middle Asia and North America. It is important to identify a tularemia infection promptly in order to initiate the correct antibiotic treatment. A rapid identification of the causative F. tularensis variety gives additional clinical information. In recent years, several genomes of various Francisella strains have been ...
The present invention includes (i) a bacterial Ig-like domain protein fragment having the amino acid sequence shown in SEQ ID NO: 2 (orf405B) or a protein having at least 80% similarity thereto, and (ii) shown in SEQ ID NO: 8. Provided is an immunogenic composition comprising a putative lipoprotein having an amino acid sequence (orf3526) or a combination of proteins having at least 80% similarity thereto. In certain embodiments, the immunogenic composition further comprises (iii) an upec1232 having the amino acid sequence shown in SEQ ID NO: 4, or a protein having at least 80% similarity thereto.
Mouse monoclonal antibody raised against Francisella tularensis LPS. Pooled water-soluble antigens from Francisella tularensis (vaccine strain). (MAB3123) - Products - Abnova
BackgroundThe objective of the study was to analyse the evolution of Bordetella pertussis population and the influence of herd immunity in different areas of the world where newborns and infants are highly vaccinated.MethodologyThe analysis was performed using DNA microarray on 15 isolates, PCR on 111 isolates as well as GS-FLX sequencing technology on 3 isolates and the B. pertussis reference strain, Tohama I.Principal FindingsOur analyses demonstrate that the current circulating isolates are continuing to lose genetic material as compared to isolates circulating during the pre-vaccine era whatever the area of the world considered. The lost genetic material does not seem to be important for virulence. Our study confirms that the use of whole cell vaccines has led to the control of isolates that were similar to vaccine strains. GS-FLX sequencing technology shows that current isolates did not acquire any additional material when compared with vaccine strains or with isolates of the pre-vaccine era and
Aussie researchers say that an initial trial of an experimental vaccine designed to protect koalas from the infectious disease chlamydia has shown positive results.
Physician reviewed meningococcal polysaccharide vaccine patient information - includes meningococcal polysaccharide vaccine description, dosage and directions.
The genes coding for outer surface protein OspC from 22 Borrelia burgdorferi strains isolated from patients with Lyme borreliosis were cloned and sequenced. For reference purposes, the 16S rRNA genes from 17 of these strains were sequenced after being cloned. The deduced OspC amino acid sequences were aligned with 12 published OspC sequences and revealed the presence of 48 conserved amino acids. On the basis of the alignment, OspC could be divided into an amino-terminal relatively conserved region and a relatively variable region in the central portion. The distance tree obtained divided the ospC sequences into three groups. The first group contained ospC alleles from all (n = 13) sensu stricto strains, the second group contained ospC alleles from seven Borrelia afzelii strains, and the third group contained ospC alleles from five B. afzelii and all (n = 9) Borrelia garinii strains. The ratio of the mean number of synonymous (dS) and nonsynonymous (dN) nucleotide substitutions per site ...
To estimate the effectiveness of pneumococcal polysaccharide vaccine, we serotyped isolates submitted to the Pneumococcal Sentinel Surveillance System from 1984 to 1996 from 48 vaccinated and 125 unvaccinated children 2 to 5 years of age. Effectiveness against invasive disease caused by serotypes included in the vaccine was 63%. Effectiveness against serotypes in the polysaccharide vaccine but not in a proposed seven-valent protein conjugate vaccine was 94%.
Pneumovax® 23 (23-valent pneumococcal polysaccharide vaccine, 23vPPBV) (1 dose), Pneumovax 23, Swindon Medical Company Limited. Administered a single dose to 2 years of age and older.Pneumonia is the 2nd leading cause of death in HK. Streptococcus pneumoniae is one of the common bacteria causing pneumonia (lung infection) and serious diseases; for example, meningitis, otitis media, sepsis and even death.According to the recommendations of the Hong Kong Centre for Health Protection: All aged 2 or above or high-risk elderly persons aged 65 or above should have pneumococcal vaccination, and high-risk individuals should be vaccinated with a 13-valent conjugate -The vaccination injection process is handled by medical professional.
Children are able to respond to protein antigens before they can respond to polysaccharide antigens. The response to pneumococcal polysaccharide vaccine is poor before the age of 2 years and some older children with recurrent respiratory infection also respond poorly to the 23-valent pneumococcal polysaccharide vaccine. Protein conjugate vaccines have been shown to induce significant antibody responses in young infants and now researchers in New Orleans, USA (Ricardo U Sorensen and colleagues, Pediatric Infectious Disease Journal 1998;17:685-91) have shown response to a heptavalent conjugate vaccine in children who did not respond to the polysaccharide vaccine.. They studied 95 children aged 2-13 years who had been referred because of recurrent respiratory infections and who did not have immunoglobulin or IgG subclass deficiencies. After a single dose of 23-valent pneumococcal polysaccharide vaccine the subjects were divided into three groups on the basis of IgG antibody response to nine ...

Smallpox Vaccine: Contraindications, Administration, and Adverse Reactions - American Family PhysicianSmallpox Vaccine: Contraindications, Administration, and Adverse Reactions - American Family Physician

... allergy to the vaccine or its components, moderate or severe intercurrent illness) and to treat vaccine-associated adverse ... The most serious side effects of smallpox vaccine include progressive vaccinia, postvaccinial central nervous system disease, ... approximately one in 1 million primary vaccinees and one in 4 million revaccinees will die from adverse vaccine reactions. ... It may be difficult to distinguish robust takes from bacterial infections. Robust takes occur eight to 10 days after ...
more infohttps://www.aafp.org/afp/2003/0901/p889.html

Chickenpox Or Varicella Vaccine: Diseases and Conditions | Pediatric OncallChickenpox Or Varicella Vaccine: Diseases and Conditions | Pediatric Oncall

Pan-resistant bacterial infections are on the rise. Should there be a restricted use of higher antib... Vote ... Vaccine Immunogenicity & Efficacy for ACIP Recommended Vaccine Products Chickenpox or Varicella Vaccine - Patient Education >> ... Vaccine Immunogenicity & Efficacy for ACIP Recommended Vaccine Products Simultaneous Administration with Other Vaccines or ... Transmission of Vaccine-Strain VZV. Vaccine-strain VZV transmission to contacts is rare and the documented risk of transmission ...
more infohttps://www.pediatriconcall.com/articles/immunization-vaccines/chickenpox-or-varicella-vaccine/chickenpox-or-varicella-vaccine-complications

Prison Planet.com  » Oral cholera vaccine loaded with GMOs to be tested on babies worldwidePrison Planet.com » Oral cholera vaccine loaded with GMOs to be tested on babies worldwide

GM Shigella flexneri NR1 bacteria derived from the Vibrio cholera bacterial strain, which is recognized as the causative agent ... Oral cholera vaccine loaded with GMOs to be tested on babies worldwide * ... a known neurotoxin that is still being intentionally added to injectable vaccines. Based on its design, the new vaccine more ... Oral cholera vaccine developed using brain-damaging mercury. To some, this might all sound like positive progress in the ...
more infohttps://www.prisonplanet.com/oral-cholera-vaccine-loaded-with-gmos-to-be-tested-on-babies-worldwide.html

Which vaccines are used to prevent bacterial gastroenteritis?Which vaccines are used to prevent bacterial gastroenteritis?

Salmonella typhi vaccine is recommended for travelers to countries with a high incidence of this infection, persons with ... Drugs & Diseases , Gastroenterology , Bacterial Gastroenteritis Q&A Which vaccines are used to prevent bacterial ... Live attenuated, killed whole-cell, and capsular polysaccharide vaccines are available.. Vibrio vaccine is available but only ... Salmonella typhi vaccine is recommended for travelers to countries with a high incidence of this infection, persons with ...
more infohttps://www.medscape.com/answers/176400-106433/which-vaccines-are-used-to-prevent-bacterial-gastroenteritis

Bacterial Pneumonia Medication: Antibiotics, Glucocorticoids, VaccinesBacterial Pneumonia Medication: Antibiotics, Glucocorticoids, Vaccines

Vaccines. Class Summary. Pneumococcal vaccines are recommended as part of routine prophylaxis in young children (aged , 5 y) ... encoded search term (Bacterial Pneumonia) and Bacterial Pneumonia What to Read Next on Medscape. Related Conditions and ... It is indicated for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP ... Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged =65 Years: ...
more infohttps://emedicine.medscape.com/article/300157-medication

Autogenous Bacterial Vaccines in Treatment of Asthma | The BMJAutogenous Bacterial Vaccines in Treatment of Asthma | The BMJ

Autogenous Bacterial Vaccines in Treatment of Asthma Br Med J 1955; 2 :941 ... Autogenous Bacterial Vaccines in Treatment of Asthma. Br Med J 1955; 2 doi: https://doi.org/10.1136/bmj.2.4945.941 (Published ...
more infohttp://www.bmj.com/content/2/4945/941

Global Invasive Bacterial Vaccine-Preventable Diseases Surveillance - 2008-2014Global Invasive Bacterial Vaccine-Preventable Diseases Surveillance - 2008-2014

World Health Organization member states with at least one invasive bacterial vaccine-preventable diseases (IB-VPD) hospital ... TABLE 1. Characteristics of global invasive bacterial vaccine-preventable diseases (IB-VPD) sentinel surveillance network sites ... Global Invasive Bacterial Vaccine-Preventable Diseases Surveillance - 2008-2014. Jillian Murray, MSPH1,2, Mary Agócs, MD1, ... The WHO invasive bacterial and vaccine-preventable disease (IB-VPD) surveillance network includes sentinel hospitals and ...
more infohttps://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a4.htm

Federal Register
       :: 
      Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy ReviewFederal Register :: Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy Review

... and labeling of bacterial vaccines and toxoids with... ... recommendations of the Panel on Review of Bacterial Vaccines ... Bacterial vaccines and bacterial antigens with "no U.S. standard of potency," (2) bacterial vaccines and toxoids with standards ... Because of the variety of possible vaccine types, e.g., live vaccines, killed vaccines, toxoids, bioengineered vaccines, ... G. Assuring Adequate Supplies of Bacterial Vaccines and Toxoids; Establishment of a National Vaccine Commission. The Panel ...
more infohttps://www.federalregister.gov/documents/2004/12/29/04-28322/biological-products-bacterial-vaccines-and-toxoids-implementation-of-efficacy-review

Burn Wound Infections Medication: Antibacterial, Topical, Vaccine, Inactivated (Bacterial)Burn Wound Infections Medication: Antibacterial, Topical, Vaccine, Inactivated (Bacterial)

Vaccine, Inactivated (Bacterial). Class Summary. These agents are used for tetanus immunization. A booster injection against ... Contribution of bacterial and viral infections to attributable mortality in patients with severe burns: an autopsy series. ... At physiologic pH, the salt dissociates to a cation that binds to negatively charged bacterial cell walls and extramicrobial ... Lachiewicz AM, Hauck CG, Weber DJ, Cairns BA, van Duin D. Bacterial Infections After Burn Injuries: Impact of Multidrug ...
more infohttps://emedicine.medscape.com/article/213595-medication?pa=Il69UQ%252B0eRfS3HgQ2uqT5MKd2YwDrKLQcF%252F%252B4zuY%252FTl1znvS6ZAajS7Gu40giwqMwbRUNf9X4DsWMEeL%252FdJuA8xINcH%252BsxRbWLj4dpGggpU%253D

Browsing Publications by Subject Bacterial VaccinesBrowsing Publications by Subject "Bacterial Vaccines"

Oral enteric bacterial vaccines : report of a WHO scientific group [‎meeting held in Geneva from 2 to 8 November 1971]‎  ... WHO Scientific Group on Oral Enteric Bacterial Vaccines; World Health Organization (‎Ginebra : Organización Mundial de la ... WHO Scientific Group on Oral Enteric Bacterial Vaccines; World Health Organization (‎Genève : Organisation mondiale de la ... WHO Scientific Group on Oral Enteric Bacterial Vaccines; World Health Organization (‎World Health OrganizationWorld Health ...
more infohttps://extranet.who.int/iris/restricted/handle/10665/26724/browse?authority=Bacterial+Vaccines&type=mesh

Estimating Meningitis Hospitalization Rates for Sentinel Hospitals Conducting Invasive Bacterial Vaccine-Preventable Diseases...Estimating Meningitis Hospitalization Rates for Sentinel Hospitals Conducting Invasive Bacterial Vaccine-Preventable Diseases...

Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland. Chris Van Beneden, Thomas Taylor, Div of Bacterial ... World Health Organization Global Invasive Bacterial Vaccine-Preventable Diseases (IB-VPD), WHO-coordinated IB-VPD network, ... Surveillance tools: field guide for tier 1 meningitis invasive bacterial vaccine preventable diseases (IB-VPD) surveillance; ... The World Health Organization (WHO)-coordinated Global Invasive Bacterial Vaccine-Preventable Diseases (IB-VPD) sentinel ...
more infohttps://www.cdc.gov/mmwr/preview/mmwrhtml/mm6239a2.htm

Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea | EurekAlert! Science NewsClinical results indicate vaccine candidate highly efficacious against bacterial diarrhea | EurekAlert! Science News

... indicate that a live attenuated enterotoxigenic Escherichia coli vaccine candidate, given in combination with a novel adjuvant ... Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea Vaccine/adjuvant combination against ... Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea. PATH. Funder. The research was ... Currently, no licensed vaccines targeting ETEC exist. The study was conducted by PATH in collaboration with Johns Hopkins ...
more infohttps://www.eurekalert.org/pub_releases/2014-10/p-cri102414.php

Sentinel surveillance of invasive bacterial vaccine-preventable diseases and rotavirus gastroenteritisSentinel surveillance of invasive bacterial vaccine-preventable diseases and rotavirus gastroenteritis

... View/. Open. B5066.pdf ... An intercountry workshop on sentinel surveillance of invasive bacterial vaccine-preventable diseases (‎IB-VPD)‎ and rotavirus ... 2013)‎. Sentinel surveillance of invasive bacterial vaccine-preventable diseases and rotavirus gastroenteritis. WHO Regional ... Furthermore, participants agreed upon the initial step of incorporating IB-VPD and RVGE surveillance into existing vaccine- ...
more infohttps://apps.who.int/iris/handle/10665/206355

Molecules | Free Full-Text | Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide VaccinesMolecules | Free Full-Text | Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines

The structures of the bacterial capsular polysaccharide (CPS) antigens, extracted and purified from microbial cultures and ... they play a major role in the functional immune response to some vaccines such as meningococcal serogroup A and Salmonella ... has been dramatically reduced over the last 25 years through the use of glycoconjugate vaccines. ... The incidence of infectious diseases caused by several bacterial pathogens such as Haemophilus influenzae type b, Streptococcus ...
more infohttp://www.mdpi.com/1420-3049/23/6/1340

Bacterial vaccines in development 1 | HSTalksBacterial vaccines in development 1 | HSTalks

Kathrin Jansen on Bacterial vaccines in development 1, part of a collection of online lectures. ... a brief overview of licensed bacterial vaccines, and some examples of bacterial vaccines in development, to discuss key ... Other Talks in the Series: Vaccines. HIV vaccine development HIV vaccine development ... So they are real life examples of bacterial vaccine development. Specifically, we will touch on vaccines in development to ...
more infohttps://hstalks.com/t/3125/bacterial-vaccines-in-development-1/?biosci

Bacterial vaccines in development 1 | HSTalksBacterial vaccines in development 1 | HSTalks

Kathrin Jansen on Bacterial vaccines in development 1, part of a collection of online lectures. ... a brief overview of licensed bacterial vaccines, and some examples of bacterial vaccines in development, to discuss key ... Other Talks in the Series: Vaccines. HIV vaccine development HIV vaccine development ... So they are real life examples of bacterial vaccine development. Specifically, we will touch on vaccines in development to ...
more infohttps://hstalks.com/t/3125/bacterial-vaccines-in-development-1/

Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines,...Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines,...

Bacterial Vaccines, Immunomodulators available in on Powells.com, also read synopsis and reviews. ... Bacterial vaccines.. Subject:. Aids. Subject:. Bacterial Vaccines -- immunology -- congresses.. Subject:. HIV. Subject:. ... Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines, ...
more infohttp://www.powells.com/book/immunobiology-of-proteins-peptides-vi-9780306440380

Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens.  - PubMed - NCBIAntigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. - PubMed - NCBI

Vaccine. 2005 Mar 18;23(17-18):2035-41.. Antigenome technology: a novel approach for the selection of bacterial vaccine ... in order to select the most promising candidates for the development of subunit vaccines against the targeted bacterial ... We have applied this technology to several bacterial pathogens of the genera Staphylococcus and Streptococcus and have, as a ... A novel approach for the identification of protein antigens from bacterial pathogens was previously developed in our laboratory ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/15755567?dopt=Abstract

Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?

... Daniel Y. Bargieri,1 ... "Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?," Journal of ...
more infohttps://www.hindawi.com/journals/jpr/2011/965369/cta/

Bacterial Influenza Vaccine (Combined) - Parke, Davis & Co. | National Museum of American HistoryBacterial Influenza Vaccine (Combined) - Parke, Davis & Co. | National Museum of American History

Bacterial Influenza Vaccine (Combined) - Parke, Davis & Co. Bacterial Influenza Vaccine (Combined) - Parke, Davis & Co.. a" ... Vaccines See more items in. Medicine and Science: Medicine The Antibody Initiative Health & Medicine Antibody Initiative: ...
more infohttp://americanhistory.si.edu/collections/search/object/nmah_719505

Diphtheria vaccines | Bacterial vaccines | VaccinesDiphtheria vaccines | Bacterial vaccines | Vaccines

Bacterial vaccines , Vaccines Brokerage service for pharmaceutical and parapharmaceutical products active ingredients and ...
more infohttps://goldpharma.com/article/11017/lang/ENGLISH/t/diphtheria%20vaccines/

Typhoid vaccines | Bacterial vaccines | VaccinesTyphoid vaccines | Bacterial vaccines | Vaccines

Bacterial vaccines , Vaccines Brokerage service for pharmaceutical and parapharmaceutical products active ingredients and ...
more infohttps://goldpharma.com/article/11025/lang/ENGLISH/t/typhoid%20vaccines/

New bacterial signaling molecule could lead to improved vaccines | Berkeley NewsNew bacterial signaling molecule could lead to improved vaccines | Berkeley News

New bacterial signaling molecule could lead to improved vaccines. By Robert Sanders, Media relations, May 27, 2010. July 9, ... These vaccine-grade bacteria could be engineered to ramp up production of the signaling molecule or ramp up the number of pumps ... What he learns could help boost the effectiveness of a Listeria vaccine, but he also hopes to use the bacterias powerful ... "We think this could translate directly into better vaccines," said Daniel Portnoy, UC Berkeley professor of molecular and cell ...
more infohttps://news.berkeley.edu/2010/05/27/listeriavaccine/

Tailor-made vaccines could almost halve rates of serious bacterial diseaseTailor-made vaccines could almost halve rates of serious bacterial disease

... * Protein closely linked to commonest cause of ... Tailor-made vaccines could almost halve rates of serious bacterial disease. Innovative study points the way to more effective ... Global Strep A vaccine one step closer. The search for a global Strep A vaccine has narrowed after researchers sequenced the ... The study simulated the performance of vaccines over time to assess the risk of vaccine-targeted strains being replaced by ...
more infohttps://www.bionity.com/en/news/1164949/tailor-made-vaccines-could-almost-halve-rates-of-serious-bacterial-disease.html

Is there a vaccine that can prevent one from getting bacterial meningitis? | eNotesIs there a vaccine that can prevent one from getting bacterial meningitis? | eNotes

Is there a vaccine that can prevent one from getting bacterial meningitis? and find homework help for other Science questions ... Yes, there are vaccines to prevent bacterial meningitis, an inflammation of the membranes around the brain and spinal cord. ... Yes, there are vaccines to prevent bacterial meningitis, an inflammation of the membranes around the brain and spinal cord. ... Is there a vaccine that can prevent one from getting bacterial meningitis?. ...
more infohttps://www.enotes.com/homework-help/there-vaccine-that-can-prevent-one-from-getting-190447
  • Risk of herpes zoster is lower among immunocompetent children immunized with varicella vaccine than among children who have had natural varicella infection. (pediatriconcall.com)
  • Smallpox vaccination carries some serious risks: approximately one in 1 million primary vaccinees and one in 4 million revaccinees will die from adverse vaccine reactions. (aafp.org)
  • Varicella Disease Burden and Varicella Vaccines / WHO SAGE Meeting April 2, 2014 by CDC http://www.who.int/immunization/sage/meetings/2014/april/2_SAGE_April_VZV_Seward_Varicella.pdf 2. (pediatriconcall.com)
  • Family physicians must learn to screen potential vaccinees for contraindications (e.g., immunodeficiency, immunosuppression, certain skin and eye diseases, pregnancy, lactation, allergy to the vaccine or its components, moderate or severe intercurrent illness) and to treat vaccine-associated adverse reactions. (aafp.org)
  • Vaccine recipients with varicella breakthrough disease are rarely contagious , typically experience a faster recovery and have no risk for complications. (pediatriconcall.com)
  • Participants will be instructed to literally consume a cocktail of mercury-resistant, GM Shigella flexneri NR1 bacteria derived from the Vibrio cholera bacterial strain, which is recognized as the causative agent of the gastroenteritis disease known as cholera. (prisonplanet.com)
  • According to the filing, the GM cholera strain used in the vaccine has essentially been artificially neutralized to prevent the toxic molecules that would otherwise cause the disease from being produced. (prisonplanet.com)
  • California-based vaccine manufacturer PaxVax has reportedly submitted an application to begin international trials of a novel oral cholera vaccine that contains live, genetically modified (GM) bacteria. (prisonplanet.com)
  • Then, there is the issue of the new PaxVax oral cholera vaccine having been programmed to grow in the presence of mercury, a known neurotoxin that is still being intentionally added to injectable vaccines. (prisonplanet.com)
  • Until 1972, this vaccine was routinely given to U.S. children. (aafp.org)
  • VacTruth.com reports that the new vaccine is set to be tested on more than 1,000 individuals, many of whom are young children, in a three-part clinical trial series to take place throughout Australia. (prisonplanet.com)
  • Do our children need another mercury-laden vaccine? (prisonplanet.com)
  • Vaccine-strain VZV transmission to contacts is rare and the documented risk of transmission exists only if the immunized person develops a rash. (pediatriconcall.com)
more